<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive License: Use of Glucocerebrosidase Activators for the Treatment of Gaucher Disease and Central Nervous System Proteinopathies, Including Parkinson's Disease</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive License: Use of Glucocerebrosidase Activators for the Treatment of Gaucher Disease and Central Nervous System Proteinopathies, Including Parkinson's Disease</h1>
    <p class="timestamp">Published: 2012-07-25 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to Lysosomal Therapeutics, Inc., a company having a place of business in Boston, Massachusetts, to practice the inventions embodied in U.S. Provisional Patent Application No. 61/420,946, filed December 8, 2010 (HHS Ref. No. E-257-2010/0-US- 01) and PCT Patent Applicat...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2012-18053</p>
    <p><strong>Publication Date:</strong> 2012-07-25</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/07/25/2012-18053/prospective-grant-of-exclusive-license-use-of-glucocerebrosidase-activators-for-the-treatment-of">https://www.federalregister.gov/documents/2012/07/25/2012-18053/prospective-grant-of-exclusive-license-use-of-glucocerebrosidase-activators-for-the-treatment-of</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-18053</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
